En in vivo interaktionsundersøgelse med warfarin indikerede, at rosiglitazon ikke interagerer med CYP2C9 - substrater in vivo.
An in vivo interaction study with warfarin indicated that rosiglitazone does not interact with CYP2C9 substrates in vivo.